| 14 Dec 2007 |
Shire expands its gastrointestinal portfolio through in-licensing Celiac disease Phase 2 product from Alba Therapeutics Corporation (83KB PDF) |
| 13 Dec 2007 |
Board Changes (77KB PDF) |
| 06 Dec 2007 |
Permission granted to challenge the High Court ruling to restrict Alzheimers’ drugs access on the NHS (16KB PDF) |
| 27 Nov 2007 |
Shire Pharmaceuticals donates over 400 laptops (21KB PDF) |
| 20 Nov 2007 |
Shire Human Genetic Therapies Appoints Dr. Whaijen Soo to Manage the R&D of its Expanding Treatment Portfolio (31KB PDF) |
| 13 Nov 2007 |
Shire pleased with Vyvanse growth - Reuters Health Summit (video) |
| 08 Nov 2007 |
Shire expands its Human Genetic Therapies pipeline through in-licensing agreement with Amicus Therapeutics (86KB PDF) |
| 05 Nov 2007 |
New non-clinical data links DYNEPO® (epoetin delta) to Reduced Angiogenic Potential (87KB PDF) |
| 01 Nov 2007 |
Further upgrade to 2007 financial guidance based on strong revenue growth; VYVANSE™ demand on track (255KB PDF) |
| 31 Oct 2007 |
David Mott appointed Non Executive Director at Shire (70KB PDF) |
| 25 Oct 2007 |
Shire launches clinical study results website (30KB PDF) |
| 17 Oct 2007 |
Third quarter 2007 results date notification (169KB PDF) |
| 08 Oct 2007 |
Reinforcing strategic focus on growth-driving global products (71KB PDF) |
| 04 Oct 2007 |
Shire’s ELAPRASE® (idursulfase) Approved in Japan For the Treatment of Hunter Syndrome (72KB PDF) |
| 01 Oct 2007 |
Shire to support appeal against outcome of Judicial Review of NICE guidance which denies newly diagnosed patients with mild Alzheimer's disease access to drugs on the NHS (23KB PDF) |
| 28 Sep 2007 |
Families Invited to Celebrate "Shire Day" at Boston Children’s Museum (20KB PDF) |
| 28 Sep 2007 |
Shire launches Clinical Study Results Database |
| 24 Sep 2007 |
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business (81KB PDF) |
| 13 Sep 2007 |
IFRS Information – First half of 2007 (140KB PDF) |
| 12 Sep 2007 |
Notification of the Exercise of an Option and Sale of Shares by a Director/PDMR. (28KB PDF) |
| 12 Sep 2007 |
Notification of the Exercise of an Option and Sale of Shares by a PDMR. (28KB PDF) |
| 12 Sep 2007 |
Statistically significant efficacy of Juvista® demonstrated in phase 2 trial using drug substance manufactured by Lonza Biologics (103KB PDF) |
| 07 Sep 2007 |
Revised NICE Guidance on Alzheimer's disease (AD) confirms reliance on the MMSE1 for majority of patients and continued exclusion from NHS treatment for those with mild AD (24KB PDF) |
| 05 Sep 2007 |
New partnership promises bright future for organic chemistry in the UK |
| 04 Sep 2007 |
Shire voluntarily withdraws a limited portion of DAYTRANA™ (methylphenidate transdermal system) patches (69KB PDF) |
| 15 Aug 2007 |
Shire supports Canada's Access to Medicines Regime (34KB PDF) |
| 15 Aug 2007 |
Expiry of Hart-Scott-Rodino waiting period for JUVISTA® (human TGFβ3) (108KB PDF) |
| 10 Aug 2007 |
Majority of patients with mild Alzheimer’s disease will remain excluded from NHS treatment despite revisions to NICE Guidance (24KB PDF) |
| 10 Aug 2007 |
Uncertainty remains for newly diagnosed patients with mild Alzheimer’s disease and their families as the Judicial Review judgement is revealed (20KB PDF) |
| 02 Aug 2007 |
Total Voting Rights (18KB PDF) |
| 31 Jul 2007 |
CNBC interview with Matthew Emmens, CEO, following Shire’s Q2 results (video) |
| 27 Jul 2007 |
Application for Share Listing (17KB PDF) |
| 26 Jul 2007 |
2007 guidance upgraded as revenue growth accelerates (196KB PDF) |
| 25 Jul 2007 |
Shire Board Changes (34KB PDF) |
| 19 Jul 2007 |
Second quarter 2007 results – Timing of investor / analyst meeting changed to 14:30 BST / 9:30 EDT (20KB PDF) |
| 18 Jul 2007 |
Second quarter 2007 results date notification - 26 July 2007 (21KB PDF) |
| 02 Jul 2007 |
Total Voting Rights (18KB PDF) |
| 29 Jun 2007 |
Shire Announces Filing of VYVANSE™ (lisdexamfetamine dimesylate) for the Treatment of ADHD in Adults (141KB PDF) |
| 25 Jun 2007 |
Shire Demonstrates Commitment To Improving Patient Adherence In End Stage Renal Disease As New Phosphate-Binder FOSRENOL® Launches In Europe (52KB PDF) |
| 25 Jun 2007 |
Notification of major interests in shares (36KB PDF) |
| 21 Jun 2007 |
Shire Receives Approvable Letter from FDA for INTUNIV™ (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD (34KB PDF) |
| 20 Jun 2007 |
Shire in-licenses JUVISTA® (human TGFβ3) from Renovo (125KB PDF) |
| 20 Jun 2007 |
Notification of major interests in shares (34KB PDF) |
| 20 Jun 2007 |
Results of the Annual General Meeting (21KB PDF) |
| 20 Jun 2007 |
Annual Information Update (33KB PDF) |
| 19 Jun 2007 |
Goldman Sachs Group and its holdings in Shire (33KB PDF) |
| 01 Jun 2007 |
Total Voting Rights (18KB PDF) |
| 29 May 2007 |
Block Listing Six Monthly Return (72KB PDF) |
| 22 May 2007 |
Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities (21KB PDF) |
| 19 May 2007 |
FDA Issues Approvable Letter for SPD465 (Triple-Bead Mixed Amphetamine Salts) for the Treatment of ADHD in Adults |
| 18 May 2007 |
Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities (27KB PDF) |
| 14 May 2007 |
Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting (36KB PDF) |
| 11 May 2007 |
Shire welcomes early date for Judicial Review of NICE decision on Alzheimer’s treatments (23KB PDF) |
| 11 May 2007 |
Retirement of Non-Executive Director and notification of the Exercise of an Option and Sale of Shares (32KB PDF) |
| 08 May 2007 |
Shire plc announces the Exercise of Over-Allotment Option in relation to Convertible Bond Offering outside the United States and to non-US persons only (21KB PDF) |
| 03 May 2007 |
VYVANSE™ (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD (37KB PDF) |
| 03 May 2007 |
VYVANSE™ (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD (37KB PDF) |
| 02 May 2007 |
Shire announces the Pricing of US$1,000 million Convertible Bonds due 2014 to be offered outside the United States and to non-US persons only (24KB PDF) |
| 02 May 2007 |
Shire announces refinancing of bank facilities connected with the recent acquisition of New River through the launch of US$1,000 million Convertible Bonds due 2014 to be offered outside the United States and to non-US persons only (25KB PDF) |
| 01 May 2007 |
Total Voting Rights (18KB PDF) |
| 25 Apr 2007 |
First quarter results - strong start to the year with upgraded guidance now including New River (103KB PDF) |
| 20 Apr 2007 |
Shire Completes Acquisition of New River (18KB PDF) |
| 18 Apr 2007 |
Shire Successfully Completes Tender Offer for New River Shares (23KB PDF) |
| 17 Apr 2007 |
FIRST QUARTER 2007 RESULTS DATE NOTIFICATION (20KB PDF) |
| 16 Apr 2007 |
Results of Extraordinary General Meeting held on 16 April 2007 (26KB PDF) |
| 16 Apr 2007 |
Notification of major interests in shares (59KB PDF) |
| 10 Apr 2007 |
Purchase of Shares by Employee Benefit Trust (28KB PDF) |
| 05 Apr 2007 |
Purchase of Shares by Employee Benefit Trust (18KB PDF) |
| 05 Apr 2007 |
Movement of shares out of the Employee Benefit Trust (18KB PDF) |
| 04 Apr 2007 |
Shire Executive Annual Incentive Plan (34KB PDF) |
| 04 Apr 2007 |
Purchase of Shares by Employee Benefit Trust (18KB PDF) |
| 04 Apr 2007 |
Movement of shares out of the Employee Benefit Trust (18KB PDF) |
| 03 Apr 2007 |
Purchase of Shares by Employee Benefit Trust (18KB PDF) |
| 03 Apr 2007 |
Application for share listing (18KB PDF) |
| 02 Apr 2007 |
Shire Executive Annual Incentive Plan (18KB PDF) |
| 02 Apr 2007 |
Total Voting Rights (18KB PDF) |
| 02 Apr 2007 |
Notification of the Exercise of an Option and Sale of Shares by a Non-Executive Director (18KB PDF) |
| 02 Apr 2007 |
Purchase of Shares by Employee Benefit Trust (28KB PDF) |
| 29 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (25KB PDF) |
| 28 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (28KB PDF) |
| 28 Mar 2007 |
Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities (27KB PDF) |
| 27 Mar 2007 |
Judicial Review of NICE decision (29KB PDF) |
| 27 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (26KB PDF) |
| 26 Mar 2007 |
Notice of EGM (32KB PDF) |
| 26 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (28KB PDF) |
| 23 Mar 2007 |
IFRS results for the year ending December 31, 2006 (100KB PDF) |
| 23 Mar 2007 |
Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities (18KB PDF) |
| 22 Mar 2007 |
Holding(s) in Company (60KB PDF) |
| 22 Mar 2007 |
Holding(s) in Company (70KB PDF) |
| 22 Mar 2007 |
Notification of the Exercise of an Option and Sale of Shares by a Director (18KB PDF) |
| 22 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (18KB PDF) |
| 21 Mar 2007 |
ADDERALL XR® - Shire Files Suit against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf (32KB PDF) |
| 20 Mar 2007 |
Shire begins external search for President of successful Human Genetic Therapies business, on retirement of David Pendergast at the end of 2007 (23KB PDF) |
| 19 Mar 2007 |
Shire Announces Expiration of Hart-Scott-Rodino Waiting Period (27KB PDF) |
| 19 Mar 2007 |
Correction to Purchase of Shares by Employee Benefit Trust (26KB PDF) |
| 16 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (25KB PDF) |
| 15 Mar 2007 |
New Human Cell-Produced Treatment for Anaemia Associated with Chronic Kidney Disease Now Available, Shire’s launch of DYNEPO® (epoetin delta) begins across Europe (52KB PDF) |
| 15 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (18KB PDF) |
| 14 Mar 2007 |
Purchase of shares by employee benefit trust (26KB PDF) |
| 13 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (25KB PDF) |
| 12 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (25KB PDF) |
| 09 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (20KB PDF) |
| 08 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (18KB PDF) |
| 06 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (20KB PDF) |
| 06 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (18KB PDF) |
| 05 Mar 2007 |
UK launch expands global reach of FOSRENOL® (156KB PDF) |
| 02 Mar 2007 |
Holding(s) in Company (58KB PDF) |
| 02 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (18KB PDF) |
| 02 Mar 2007 |
Purchase of Shares by Employee Benefit Trust (19KB PDF) |
| 28 Feb 2007 |
Director/PDMR Shareholding (21KB PDF) |
| 28 Feb 2007 |
Holding(s) in Company (60KB PDF) |
| 28 Feb 2007 |
Holding(s) in Company (56KB PDF) |
| 28 Feb 2007 |
Holding(s) in Company (70KB PDF) |
| 28 Feb 2007 |
Holding(s) in Company (59KB PDF) |
| 28 Feb 2007 |
Holding(s) in Company (55KB PDF) |
| 27 Feb 2007 |
Movement of shares out of the Employee Benefit Trust (17KB PDF) |
| 23 Feb 2007 |
FDA Approval of VYVANSE™ as a Novel Treatment for ADHD (45KB PDF) |
| 23 Feb 2007 |
Director/PDMR Shareholding (27KB PDF) |
| 23 Feb 2007 |
Employee Benefit Trust announcement (26KB PDF) |
| 22 Feb 2007 |
FOSRENOL® launches in United Kingdom today (112KB PDF) |
| 22 Feb 2007 |
Director/PDMR Shareholding (18KB PDF) |
| 20 Feb 2007 |
Shire agrees to acquire new river to gain full control of Vyvanseâ¢, its future flagship product for ADHD (52KB PDF) |
| 20 Feb 2007 |
Shire announces $800 million equity financing in connection with Acquisition Of New River (18KB PDF) |
| 20 Feb 2007 |
Result of equity placing (21KB PDF) |
| 20 Feb 2007 |
Results for the twelve months to December 31, 2006 - On time execution of operating plan delivers strong 2006 performance (207KB PDF) |
| 15 Feb 2007 |
Total Voting Rights (18KB PDF) |
| 14 Feb 2007 |
Full Year 2006 Results Date Notification - 23 February 2007 (20KB PDF) |
| 12 Feb 2007 |
Movement of shares out of the Employee Benefit Trust (18KB PDF) |
| 25 Jan 2007 |
Goldman Sachs Group and its holdings in Shire (17KB PDF) |
| 23 Jan 2007 |
Shire licenses the North American rights for SPD754 (19KB PDF) |
| 18 Jan 2007 |
Total Voting Rights (25KB PDF) |
| 12 Jan 2007 |
Goldman Sachs Group and its holdings in Shire (17KB PDF) |
| 11 Jan 2007 |
ELAPRASE® for the treatment of Hunter syndrome approved by the European Commission (28KB PDF) |
